{"id":4395,"date":"2026-05-12T19:00:00","date_gmt":"2026-05-12T17:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=6ed1f72a68759b2df32dc415a6553b70"},"modified":"2026-05-12T19:00:00","modified_gmt":"2026-05-12T17:00:00","slug":"vast-therapeutics-to-present-phase-1-data-on-first-in-class-nitric-oxide-therapy-alx1-at-the-american-thoracic-society-2026-international-conference","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=4395","title":{"rendered":"Vast Therapeutics to Present Phase 1 Data on First-in-Class Nitric Oxide Therapy ALX1 at the American Thoracic Society 2026 International Conference"},"content":{"rendered":"<p>MORRISVILLE, N.C.--(BUSINESS WIRE)--<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vasttherapeutics.com%2F&amp;esheet=54534199&amp;newsitemid=20260512866253&amp;lan=en-US&amp;anchor=Vast+Therapeutics&amp;index=1&amp;md5=d711342ff125c7eeda1e6a1c13ecdae0\" rel=\"nofollow\" shape=\"rect\">Vast Therapeutics<\/a>, a clinical-stage life science company developing nitric oxide-based medicines for serious lung diseases, will present a late-breaking poster presentation demonstrating safety and pharmacokinetic data from the Phase 1 study of its inhaled drug candidate ALX1 at the American Thoracic Society (ATS) 2026 International Conference. ALX1 contains a first-in-class, small molecule nitric oxide prodrug designed to provide dual-action anti-inflammatory and anti-microbial activity without dose-associated toxicities. ATS 2026 will take place in Orlando, Florida from May 15-20.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260512866253\/en\/2802875\/4\/vast-therapeutics.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260512866253\/en\/2802875\/22\/vast-therapeutics.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260512866253\/en\/2802875\/4\/vast-therapeutics.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260512866253\/en\/2802875\/21\/vast-therapeutics.jpg\" \/><\/a><p>\nVast Therapeutics\u2019 Chief Medical Officer Paul Bruinenberg, MD, MBA, and Chief Executive Officer Nate Stasko, PhD, will be available to discuss the company\u2019s novel NO delivery technology.<\/p><p>\n<b><span class=\"bwuline\">Poster Presentation Details<\/span><\/b><\/p><p>\n<b>Session<\/b>: B29 \u2013 The Latest in Airway Symptoms and Disease\n<br\/><b>Poster Title<\/b>: Inhaled ALX1 Safety, Tolerability, and Dose Dependent Pharmacokinetics in Phase 1 Study: A Novel Approach for Targeted Delivery of Nitric Oxide to the Lungs\n<br\/><b>Lead Presenter<\/b>: Paul Bruinenberg, MD, MBA, Vast Therapeutics\n<br\/><b>Poster Number<\/b>: 925\n<br\/><b>Presentation Date and Time<\/b>: Monday, May 18, 9:15 am - 11:15 am ET\n<br\/><b>Location<\/b>: W414AB (Level IV, OCCC West Concourse)<\/p><p>\nFor more information about Vast and ALX1, visit the company\u2019s <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fvasttherapeutics.com&amp;esheet=54534199&amp;newsitemid=20260512866253&amp;lan=en-US&amp;anchor=website&amp;index=2&amp;md5=3c0bacc03d5ca1677e4aa4c7ece209ca\" rel=\"nofollow\" shape=\"rect\">website<\/a>.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>Media Contact:<\/b><br\/>Maggie Turano, ICR Healthcare\n<br\/><a  href=\"mailto:Maggie.Turano@ICRHealthcare.com\" rel=\"nofollow\" shape=\"rect\">Maggie.Turano@ICRHealthcare.com<\/a><br\/>332-242-4318<\/p>","protected":false},"excerpt":{"rendered":"<p>MORRISVILLE, N.C.&#8211;(BUSINESS WIRE)&#8211;Vast Therapeutics, a clinical-stage life science company developing nitric oxide-based medicines for serious lung diseases, will present a late-breaking poster presentation demonstrating safety and pharmacokinetic da&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-4395","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/4395","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4395"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/4395\/revisions"}],"predecessor-version":[{"id":4396,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/4395\/revisions\/4396"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4395"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4395"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4395"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}